动脉内给药提升难治性脑膜瘤患者177Lu-HA-DOTATATE的蓄积
本研究在4例手术和放疗难治性脑膜瘤患者中,比较静脉与动脉内给予177Lu-HA-DOTATATE后的肿瘤蓄积。动脉内给药技术成功率100%,无血管造影相关或意外不良事件;患者自身对照显示平面显像靶病灶蓄积平均增加220%,SPECT/CT平均增加398%。提示动脉内肽受体放射性核素治疗安全且可显著提高示踪剂蓄积。
要点
- 动脉内给予177Lu-HA-DOTATATE技术成功率100%,未见血管造影相关或意外不良事件。
- 患者自身对照中,动脉内给药后平面显像靶病灶蓄积平均增加220%,SPECT/CT平均增加398%。
- 动脉内肽受体放射性核素治疗安全且可显著提高难治性脑膜瘤的示踪剂蓄积。
核心结论
- 动脉内肽受体放射性核素治疗显著增加难治性脑膜瘤患者的示踪剂蓄积,是安全且有前景的改进。
研究设计与样本
- 4例手术和放疗难治性脑膜瘤患者先接受至少1次静脉177Lu-HA-DOTATATE治疗,随后接受动脉内周期治疗。
- 基于注射后24小时的治疗后177Lu-HA-DOTATATE显像进行患者内和住院期间比较,并记录技术成功率和不良事件。
主要发现
- 技术成功率为100%,未发生血管造影相关或意外不良事件。
- 患者内比较显示,动脉内给药后平面显像靶病灶蓄积平均增加220%,SPECT/CT平均增加398%。
- 随访期间未发生意外不良事件。
关键数值与推荐
- 动脉内给药后平面显像靶病灶蓄积较静脉给药平均增加220%。
- 动脉内给药后SPECT/CT靶病灶蓄积较静脉给药平均增加398%。
临床怎么用
- 对手术和放疗难治性脑膜瘤患者,动脉内给予177Lu-HA-DOTATATE可提高靶病灶蓄积且安全性可接受。
- 尚需前瞻性研究确定动脉内肽受体放射性核素治疗在疗效和生存方面的获益。
局限性
- 样本量仅4例,结果需更大规模前瞻性研究验证。
- 疗效和生存获益尚未确定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Intravenous 177Lu-high-affinity (HA)-DOTATATE has shown promising results for the treatment of surgery- and radiotherapy-refractory meningiomas. We aimed to investigate the added value of intraarterial administration. Methods: Patients underwent at least 1 intravenous 177Lu-HA-DOTATATE treatment first and subsequent intraarterial cycles. Inpatient and intrapatient comparison was based on posttreatment 177Lu-HA-DOTATATE imaging 24 h after injection. The technical success rate and adverse events were recorded. Results: Four patients provided informed consent. The technical success rate was 100%, and no angiography-related or unexpected adverse events occurred. Intrapatient comparison showed an increased target lesion accumulation on both planar imaging (mean, +220%) and SPECT/CT (mean, +398%) after intraarterial administration, compared with intravenous administration. No unexpected adverse events occurred during follow-up. Conclusion: Intraarterial peptide receptor radionuclide therapy significantly increases tracer accumulation and is a safe and promising improvement for salvage meningioma patients. Future prospective studies on intraarterial peptide receptor radionuclide therapy are needed to determine the gain in efficacy and survival.
引用
- Vonken EPA, Bruijnen RCG, Snijders TJ, et al. Intraarterial Administration Boosts 177Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients. J Nucl Med. 2021. PMID: 34301783. doi:10.2967/jnumed.121.262491
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。